Xeris Biopharma Holdings, Inc. (XERS) Investor Relations Documents

Xeris Biopharma Holdings, Inc. (XERS) investor relations documents from the company's IR site: 1 presentation, 39 press releases; latest deck 2026-08-07. Read in-app with summaries. First-party data.

View Presentation: Xeris Biopharma’s August 2026 presentation outlines a growth strategy targeting $385-390M in 2026 revenue, driven by Recorlev and the pipeline candidate XP-8121.

Investor relations documents — source: company IR site
PublishedTypeDocument
2026-08-07PresentationView Presentation
2026-08-06Press releasePress release
2026-08-06Press releaseXeris Biopharma Reports Second Quarter 2026 Financial Results
2026-07-23Press releasePress release
2026-07-23Press releaseXeris Biopharma to Report Second Quarter 2026 Financial Results on August 6, 2026
2026-07-02Press releasePress release
2026-07-02Press releasePress release
2026-07-02Press releaseXeris Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
2026-07-02Press releaseCORRECTING and REPLACING Xeris Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
2026-06-30Press releasePress release
2026-06-30Press releaseXeris Announces Updates to Its Board of Directors
2026-06-11Press releasePress release
2026-06-11Press releasePress release
2026-06-11Press releaseXeris Biopharma Announces Private Exchange of Convertible Notes
2026-06-11Press releaseXeris Biopharma Announces Notice of Allowance From U.S. Patent and Trademark Office for New Patent Covering KEVEYIS®
2026-05-07Press releasePress release
2026-05-07Press releaseXeris Biopharma Reports First Quarter 2026 Financial Results
2026-04-23Press releasePress release
2026-04-23Press releaseXeris Biopharma to Report First Quarter 2026 Financial Results on May 7, 2026
2026-04-03Press releasePress release
2026-04-03Press releaseXeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2026-03-02Press releasePress release
2026-03-02Press releaseXeris Biopharma Reports Record Performance for Fourth Quarter and Full Year 2025 and Provides Full Year 2026 Guidance
2026-02-26Press releasePress release
2026-02-26Press releaseXeris Biopharma Subsidiaries File Recorlev® Patent Infringement Lawsuit
2026-02-17Press releasePress release
2026-02-17Press releaseXeris Biopharma to Report Full Year 2025 Financial Results and Provide Full Year 2026 Guidance on March 2, 2026
2026-01-08Press releasePress release
2026-01-08Press releaseXeris Expects to Deliver Record Fourth Quarter and Full-Year 2025 Total Revenue
2026-01-02Press releasePress release
2026-01-02Press releaseXeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Press releaseXeris Biopharma Posts Record Financial Results for the Third Quarter 2025
Press releaseXeris Biopharma to Report Third Quarter 2025 Financial Results on November 6, 2025
Press releaseXeris Biopharma Reports Record Financial Results for the Second Quarter 2025 and Raises Full Year Revenue Guidance
Press releaseXeris Biopharma to Report Second Quarter 2025 Financial Results on August 7, 2025
Press releaseXeris Biopharma Reports Record First Quarter 2025 Financial Results
Press releaseXeris Biopharma to Report First Quarter 2025 Financial Results on May 8, 2025
Press releaseXeris Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Highlights Pipeline Progress
Press releaseXeris Pharmaceuticals Reinforces the Importance of GVOKE™ PFS for People With Diabetes
Press releaseXeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

XERS overview · XERS earnings · XERS financials · XERS KPIs · XERS documents · XERS ownership · XERS peers

Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.